Will WuXi Benefit From Rival ShangPharma Going Private?
This article was originally published in PharmAsia News
Executive Summary
China’s second largest CRO ShangPharma is likely to go private after a proposal from its founder, and some say the exit may also help its larger rival WuXi PharmaTech.
You may also be interested in...
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
Chinese Pharma Cracking The U.S. Market Via Reverse Mergers Draw Attention From Authorities
HONG KONG - A number of Chinese companies publicly traded in the U.S., including several in the pharmaceutical space, have come under the spotlight in the last 18 months after getting to market through reverse mergers
China's Second-largest CRO Seeks Initial Public Offering In The U.S.
Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18